News & Events
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024 On track to deliver additional analyses from BEACON and AURORA in Q2 2024 Plan to present updated data from the phase 1b/2 study of DISC-0974 in anemia of
More News
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPP The CNPV program is designed to...
read more
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
Disc is seeking accelerated approval and priority review of its NDA submission FDA decision to accept and file the NDA for review...
read more
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more